Perfect match: mTOR inhibitors and tuberous sclerosis complex

Area of Science:

• Genetics and Molecular Biology
• Neurology
• Pharmacology

Background:

• Tuberous sclerosis complex (TSC) is an autosomal dominant disorder with multisystemic manifestations.
• Neurological and organ dysfunction in TSC significantly impacts patient quality of life and survival.
• Clinical features of TSC are largely attributed to the hyperactive mammalian target of rapamycin (mTOR) pathway due to TSC1/TSC2 mutations.

Purpose of the Study:

• To review the current use of mTOR inhibitors in TSC management.
• To evaluate the efficacy and safety of mTOR inhibitors for TSC.
• To highlight the need for predictive biomarkers for mTOR inhibitor response in TSC.

Main Methods:

• Literature review of studies on mTOR inhibitors in TSC.
• Analysis of clinical trial data regarding efficacy and adverse events.
• Synthesis of current understanding of mTOR pathway in TSC pathogenesis.

Main Results:

• mTOR inhibitors (rapamycin/everolimus) offer therapeutic potential for TSC.
• Adverse events (stomatitis, infections, menstrual disorders) and variable patient responses limit widespread use.
• Lack of reliable indicators to predict treatment efficacy is a significant challenge.

Conclusions:

• mTOR inhibitors are valuable in TSC treatment but require careful monitoring due to side effects and variable efficacy.
• Further research is needed to identify biomarkers for predicting patient response to mTOR inhibitors.
• Optimizing TSC management necessitates personalized treatment strategies guided by predictive indicators.